Drug Profile
Research programme: oncolytic viral cancer therapeutics - Codagenix
Alternative Names: CDX-Onc; CDX-ONC-BC; CDX-ONC-NB1Latest Information Update: 04 Dec 2020
Price :
$50
*
At a glance
- Originator Codagenix
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
- No development reported Bladder cancer; Neuroblastoma
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Parenteral)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Neuroblastoma in USA (Parenteral)
- 28 Nov 2016 Preclinical trials in Bladder cancer in USA (Parenteral) ( Codagenix pipeline, November 2016)